Czechia· CZ-2901535

AUSTEDO

A deutetrabenazine product containing deutetrabenazine, registered in Czechia by Teva GmbH, Ulm. The same ATC class is registered in 9 of our 19 countries.

ATC N07XX16

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedAUSTEDOATCN07XX16REGISTER NO.CZ-2901535PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Deutetrabenazine is registered in 9 of 19 countries.

Countries holding a registration under ATC N07XX16 (deutetrabenazine), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 6 of them publish a price we can compare per daily dose

Deutetrabenazine · ATC N07XX16

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
DEUTETRABENAZINE
Manufacturer
Teva GmbH, Ulm
Country
Czechia (CZ)
ATC code
N07XX16
ATC class
Deutetrabenazine
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

219 interactions on record for deutetrabenazine.

Graded by severity as the source publishes them — 53 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Deutetrabenazine · interactions on record

219 records

  • 53 severe
  • 164 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • MetoclopramideA03FA01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deutetrabenazine in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deutetrabenazine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Austedo
  • Iceland · Austedo
  • Liechtenstein · Austedo
  • Norway · Austedo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b55e89fb-17ca-42f5-81b5-3c4303994ff8
GET /v1/drugs/b55e89fb-17ca-42f5-81b5-3c4303994ff8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "TBL PRO",
  "source": "sukl",
  "strength": "12+24+30+36+42+48MG",
  "pack_size": "7+7+7+7+7+7",
  "substance": "DEUTETRABENAZINE",
  "cz_kod_sukl": "2901535",
  "product_type": "CH",
  "substance_codes": "20664,20664,20664,20664,20664,20664",
  "registration_state": "R",
  "registration_number": "EU/1/25/1956/001"
}

See everything about deutetrabenazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.